A Long-Standing Question in B Cell Biology
Textbooks have long taught that once a B cell completes V(D)J recombination in the bone marrow and expresses a unique B cell receptor (BCR), its antigen-binding identity is locked for life. However, a fundamental question has intrigued our lab for years: what happens to mature peripheral B cells whose receptors never encounter an antigen or whose surface signals go silent? Do they remain idle indefinitely, or do they possess a hidden mechanism to rewrite their identity? This question traces back to research initiated by the corresponding author (J.H.W.) during her postdoctoral training, which investigated secondary V(D)J recombination and receptor editing in mature B cells. Those early studies showed that mature B cells retain the capacity to alter their light chains in vitro, proving that receptor commitment might be more dynamic than assumed by the field. Yet whether, why, and under what physiological circumstances peripheral B cells revise their heavy or light chain identity in vivo remain a central mystery in B cell biology.
Why Tracking Receptor Changes Is Challenging
In a normal immune system, mature B cells express millions of different B cell receptors (BCRs). If an individual B cell rewrites its receptor identity, its new sequence simply blends into the vast, highly diverse background population. Tracking that single event in a polyclonal repertoire is virtually impossible, akin to identifying a specific drop of water in the ocean. To overcome this hurdle, we used a specialized BCR knock-in mouse model (VDJ9/k5), in which virtually all mature B cells express an identical receptor, composed of a VDJ9 heavy chain and a k5 light chain, against hen egg lysozyme (HEL), a protein found in egg whites. Because mice naturally lack the HEL antigen, these anti-HEL receptors remain unengaged. This monoclonal baseline enables us to track B cells that alter their identity and directly evaluate how the absence of antigen engagement influences B cell fate.
Why and When B Cells Revise Their Identity
In our newly published paper, we addressed this fundamental question using the HEL BCR knock-in mouse model. By placing B cells into this "idle," signal-deprived state, we created a window to see what happens when BCR signaling goes quiet. This system revealed a fundamental discovery: B cells do not sit passively when their receptors are unengaged. Instead, a sustained lack of BCR signaling triggers them to actively rewrite their identity. We discovered that when peripheral B cells experience weak or absent BCR signals, they upregulate the endonuclease RAG1 and reactivate V(D)J recombination at the immunoglobulin heavy chain (Igh) locus. Through a process known as VH gene replacement (VHR), an upstream VH segment invades the existing VDJ exon, creating a novel receptor specificity and altering the cell's identity. By tuning BCR signaling strength (either dampening signals with the BTK inhibitor Ibrutinib or enhancing them using a gain-of-function Cd79bY195H mutant allele), we demonstrated that BCR signaling acts as a continuous repressor of RAG expression. When BCR signaling drops below a critical threshold, RAG is unleashed to initiate VHR.
The Double-Edged Sword of Rewriting Genomic DNA
Rewriting antigen receptors in peripheral B cells is a high-risk gamble. Each secondary recombination event introduces RAG-initiated DNA double-stranded breaks (DSBs) at the Igh locus and potential off-target cutting at cryptic recombination signal sequences (RSS)—sequence motifs across the genome that accidentally mimic RAG target sites. In healthy peripheral B cells, accumulating these RAG-induced DSBs triggers rapid apoptosis, providing a vital safety mechanism to clear damaged cells. However, when we deleted the tumor suppressor adaptor TRAF3, this protective checkpoint broke down. TRAF3-deficient B cells bypassed DSB-induced apoptosis by activating the non-canonical NF-kB2 pathway. Instead of dying, these damaged, VHR-experienced B cells survived, accumulated genetic lesions, and underwent abnormal oligoclonal expansion, putting them on a path toward lymphoma.
Implications for Human Disease and Oncogenesis
Our findings in mouse models directly mirror recent breakthroughs in human lymphoma research. Clinical studies have shown that over 65% of aggressive high-grade B-cell lymphomas undergo post-translational BCR silencing, resulting in an "IgH-undetectable" (IGHUND) phenotype. Just as in our mouse models, this loss of BCR signaling relieves transcriptional repression on RAG1/2, driving secondary rearrangements, intraclonal diversification, and oncogenic chromosomal translocations. Furthermore, our work highlights important considerations for targeted therapies: while BTK inhibitors effectively block tumor proliferation, chronic suppression of BCR signaling can inadvertently mimic an "idle" state, unleashing RAG in certain susceptible B-cell clones. If these cells also harbor survival mutations (such as TRAF3 loss or BCL2 overexpression), they can tolerate RAG activity, accumulate genomic instability, and undergo high-grade transformation.
Redefining B Cell Commitment and Homeostasis
Our study challenges long-standing paradigms by showing that mature B cells dynamically monitor their signaling environment, standing ready to rewrite their identity when signals fade. Elucidating the delicate balance between physiological receptor revision and genomic instability provides fundamental insights into immune homeostasis and reveals how signaling disruption can drive B-cell oncogenesis.